NewsBenzingaBarclays maintient sa recommandation de surpondérer Ultragenyx Pharmaceutical, abaisse son objectif de cours à 32 $ Barclays maintient sa recommandation de surpondérer Ultragenyx Pharmaceutical, abaisse son objectif de cours à 32 $ Benzinga 2026.11.05 19:13 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on Ashland, Raises Price Target to $82 JP Morgan Maintains Neutral on ArcBest, Raises Price Target to $164 JP Morgan Maintains Overweight on Dave, Lowers Price Target to $435 Chip Stocks Just Had Their Worst Day Since 2020: 28 of 30 Biggest Names Are in a Bear Market $1000 Invested In Novartis 5 Years Ago Would Be Worth This Much Today JP Morgan Maintains Underweight on Avis Budget Gr, Lowers Price Target to $85
